Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00853073 · ClinicalTrials.gov registry record · Phase 2

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

A Phase 2 study, sponsored by Wills Eye.

Completed
Registry status
Phase 2
Development phase
63
Enrollment target

NCT00853073 is a Phase 2 study that has completed, run by Wills Eye. The registered enrollment target is 63 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00853073, a Phase 2 study, has completed, sponsored by Wills Eye.

COMPLETED
Registry status
Phase 2
Development phase
63 participants
Enrollment target

Study Summary

The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.

Interventions

  • DRUG bevacizumab
  • OTHER balanced salt solution

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2009-02
Est. Completion 2012-01
Phase Phase 2

Sponsor

Wills Eye

59 total trials

What the Registry Record Tells You About NCT00853073

The ClinicalTrials.gov registry entry for NCT00853073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.

NCT00853073 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00853073 about?

NCT00853073 is a clinical study titled "Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?". The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.

What is the current status of trial NCT00853073?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2009-02. Estimated completion is 2012-01.

What interventions are being tested in trial NCT00853073?

The interventions under investigation include: bevacizumab (DRUG), balanced salt solution (OTHER).

Who is sponsoring clinical trial NCT00853073?

This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.